Large cell neuroendocrine carcinoma of the cervix: a case report

Large Cell Neuroendocrine Carcinoma (LCNEC) of the cervix is an extremely rare but highly aggressive type of cervical cancer and it requires multimodal therapy to improve their quality of life. At present, there are no established, standardized treatment protocols for managing large cell neuroendocr...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 14; p. 1419710
Main Authors Li, Chunmei, Wu, Maoyuan, Zhang, Wenwen, Jiang, Xiaoling, Zhang, Lixia, Wang, Gangcheng, He, Lianli
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.07.2024
Subjects
advanced cervical cancer
case report
cervical cancer treatment
large cell
Oncology
well-differentiated neuroendocrine carcinoma
case report
cervical cancer treatment
large cell
advanced cervical cancer
well-differentiated neuroendocrine carcinoma
Online AccessGet full text

Cover

More Information
Summary:Large Cell Neuroendocrine Carcinoma (LCNEC) of the cervix is an extremely rare but highly aggressive type of cervical cancer and it requires multimodal therapy to improve their quality of life. At present, there are no established, standardized treatment protocols for managing large cell neuroendocrine carcinoma of the cervix. In this report, we present a case of a patient with cervical LCNEC, Who was a 39-year-old woman who presented with irregular vaginal bleeding accompanied by lower abdominal distension for over a month. Examination revealed a cauliflower-like cervical mass approximately 4cm in diameter, with the normal cervical architecture distorted and partially fused to the vaginal wall. Following further investigations, the stage assigned was IVB, and who was started on neoadjuvant chemotherapy with the TC (paclitaxel + carboplatin) regimen but during neoadjuvant chemotherapy, The patient developed a vaginal urinary leakage. Then, The patient underwent a comprehensive treatment regimen that included pelvic exenteration, urinary system reconstruction, pelvic floor reconstruction, and chemotherapy. Given the patient's positive immunohistochemistry for EGFR, the treatment was combined with the anti-angiogenic drug, bevacizumab. The patient achieved complete remission following the comprehensive treatment. Through this case to explore individualized treatment for cervical LCNEC.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Edited by: Giuseppe Giaccone, Cornell University, United States
Mattia Tarascio, Cannizzaro Hospital, Italy
Reviewed by: Basilio Pecorino, Kore University of Enna, Italy
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1419710